[Ocular burns].
Merle H, Gérard M, Schrage N.
J Fr Ophtalmol. 2008 Sep;31(7):723-34. doi: 10.1016/s0181-5512(08)74391-2.
Chemical injuries of the eye: current concepts in pathophysiology and therapy.
Wagoner MD.
Surv Ophthalmol. 1997 Jan-Feb;41(4):275-313. doi: 10.1016/s0039-6257(96)00007-0.
[Physiopathology of eye burns].
Renard G.
J Fr Ophtalmol. 2004 Dec;27(10):1164-9. doi: 10.1016/s0181-5512(04)96290-0.
[Clinical aspects of corneal burns].
Borderie V.
J Fr Ophtalmol. 2004 Dec;27(10):1170-4. doi: 10.1016/s0181-5512(04)96291-2.
Inflammation, vascularization and goblet cell differences in LSCD: Validating animal models of corneal alkali burns.
Kethiri AR, Raju E, Bokara KK, Mishra DK, Basu S, Rao CM, Sangwan VS, Singh V.
Exp Eye Res. 2019 Aug;185:107665. doi: 10.1016/j.exer.2019.05.005. Epub 2019 May 13.
Therapeutic potential of trichostatin A to control inflammatory and fibrogenic disorders of the ocular surface.
Kitano A, Okada Y, Yamanka O, Shirai K, Mohan RR, Saika S.
Mol Vis. 2010 Dec 31;16:2964-73.
Management of severe ocular burns with symblepharon.
Shi W, Wang T, Gao H, Xie L.
Graefes Arch Clin Exp Ophthalmol. 2009 Jan;247(1):101-6. doi: 10.1007/s00417-008-0934-0. Epub 2008 Sep 3.
[Limits of conservative and surgical therapy of chemical burns of the conjunctiva and cornea].
Straub W.
Buch Augenarzt. 1982;(89):1-8.
[Experimental validation of the use of RNA hydrolysate (ENKAD) in chemical burns of the cornea].
Andrushkova OA, Plevinskikh VP, Iakimenko SA.
Oftalmol Zh. 1990;(6):338-43.
The effects of chemical injury on the ocular surface.
Pfister RR.
Ophthalmology. 1983 Jun;90(6):601-9. doi: 10.1016/s0161-6420(83)34509-7.
